{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T08:50:33Z","timestamp":1783759833778,"version":"3.55.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"am","delay-in-days":346,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010486","name":"Teijin Pharma Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010486","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.ijcard.2021.11.076","type":"journal-article","created":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T22:52:52Z","timestamp":1638485572000},"page":"127-133","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Effect of febuxostat on clinical outcomes in patients with hyperuricemia and cardiovascular disease"],"prefix":"10.1016","volume":"349","author":[{"given":"Masaaki","family":"Konishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunao","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Uchiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiichi","family":"Tokutake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Wakasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Hiramitsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masako","family":"Waki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Jinnouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Kakuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisao","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Tsujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiko","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Hisatome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Ohya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisao","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ijcard.2021.11.076_bb0005","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.1038\/s41598-018-22570-9","article-title":"Prevalence and correlates of hyperuricemia in the middle-aged and older adults in China","volume":"8","author":"Song","year":"2018","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.ijcard.2021.11.076_bb0010","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/art.40807","article-title":"Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the National Health and nutrition examination survey, 2007\u20132016","volume":"71","author":"Chen-Xu","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.ijcard.2021.11.076_bb0015","doi-asserted-by":"crossref","first-page":"6681","DOI":"10.1038\/s41598-019-43241-3","article-title":"Hyperuricemia has increased the risk of progression of chronic kidney disease: propensity score matching analysis from the KNOW-CKD study","volume":"9","author":"Oh","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijcard.2021.11.076_bb0020","doi-asserted-by":"crossref","first-page":"19520","DOI":"10.1038\/srep19520","article-title":"Hyperuricemia and the risk for coronary heart disease morbidity and mortality a systematic review and dose-response meta-analysis","volume":"6","author":"Li","year":"2016","journal-title":"Sci. Rep."},{"issue":"16","key":"10.1016\/j.ijcard.2021.11.076_bb0025","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.lfs.2004.10.031","article-title":"Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase\/xanthine dehydrogenase","volume":"76","author":"Takano","year":"2005","journal-title":"Life Sci."},{"issue":"4 Suppl 2","key":"10.1016\/j.ijcard.2021.11.076_bb0030","first-page":"S44","volume":"17","author":"Kamatani","year":"2011","journal-title":"J. Clin. Rheumatol."},{"issue":"13","key":"10.1016\/j.ijcard.2021.11.076_bb0035","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout","volume":"378","author":"White","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"10264","key":"10.1016\/j.ijcard.2021.11.076_bb0040","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/S0140-6736(20)32234-0","article-title":"Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial","volume":"396","author":"Mackenzie","year":"2020","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.ijcard.2021.11.076_bb0045","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1093\/eurheartj\/ehz119","article-title":"Febuxostat for cerebral and CaRdiorenovascular events PrEvEntion StuDy","volume":"40","author":"Kojima","year":"2019","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.ijcard.2021.11.076_bb0050","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jjcc.2016.02.015","article-title":"Rationale, design, and baseline characteristics of a study to evaluate the effect of febuxostat in preventing cerebral, cardiovascular, and renal events in patients with hyperuricemia","volume":"69","author":"Kojima","year":"2017","journal-title":"J. Cardiol."},{"issue":"12","key":"10.1016\/j.ijcard.2021.11.076_bb0055","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.3949\/ccjm.73.12.1059","article-title":"Role of uric acid in hypertension, renal disease, and metabolic syndrome","volume":"73","author":"Heinig","year":"2006","journal-title":"Cleve. Clin. J. Med."},{"issue":"11","key":"10.1016\/j.ijcard.2021.11.076_bb0060","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1002\/art.40583","article-title":"New perspectives in rheumatology: implications of the cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular morbidities trial and the associated Food and Drug Administration public safety alert","volume":"70","author":"Choi","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.ijcard.2021.11.076_bb0065","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0002-9343(87)90441-4","article-title":"Risks and consequences in the normative aging study","volume":"82","author":"Campion","year":"1987","journal-title":"Am J Med"},{"issue":"16","key":"10.1016\/j.ijcard.2021.11.076_bb0070","doi-asserted-by":"crossref","first-page":"e840","DOI":"10.1161\/CIR.0000000000000664","article-title":"Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association","volume":"139","author":"Rangaswami","year":"2019","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ijcard.2021.11.076_bb0075","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/HJH.0000000000002600","article-title":"Relationships between diuretic-related hyperuricemia and cardiovascular events: data from the URic acid right for heArt health study","volume":"39","author":"Maloberti","year":"2021","journal-title":"J. Hypertens."},{"issue":"2","key":"10.1016\/j.ijcard.2021.11.076_bb0080","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1161\/HYPERTENSIONAHA.119.13643","article-title":"Identification of the uric acid thresholds predicting an increased Total and cardiovascular mortality over 20 years","volume":"75","author":"Virdis","year":"2020","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.ijcard.2021.11.076_bb0085","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s40292-020-00368-z","article-title":"Hyperuricemia and risk of cardiovascular outcomes: the experience of the URRAH (Uric acid right for heart Health) project","volume":"27","author":"Maloberti","year":"2020","journal-title":"High Blood Press Cardiovasc. Prev."},{"issue":"8","key":"10.1016\/j.ijcard.2021.11.076_bb0090","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1681\/ASN.2005121288","article-title":"Microalbuminuria and risk for cardiovascular disease: analysis of potential mechanisms","volume":"17","author":"Stehouwer","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"issue":"6","key":"10.1016\/j.ijcard.2021.11.076_bb0095","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1053\/j.ajkd.2018.06.028","article-title":"Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial","volume":"72","author":"Kimura","year":"2018","journal-title":"Am. J. Kidney Dis."},{"issue":"11","key":"10.1016\/j.ijcard.2021.11.076_bb0100","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002270","article-title":"Prognostic Value of Flow-Mediated Vasodilation in Brachial Artery and Fingertip Artery for Cardiovascular Events: A Systematic Review and Meta-Analysis","volume":"4","author":"Matsuzawa","year":"2015","journal-title":"J, Am Heart Assoc"},{"issue":"4","key":"10.1016\/j.ijcard.2021.11.076_bb0105","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1253\/circj.CJ-15-0068","article-title":"Secondary prevention strategy of cardiovascular disease using endothelial function testing","volume":"79","author":"Matsuzawa","year":"2015","journal-title":"Circ J"},{"issue":"22","key":"10.1016\/j.ijcard.2021.11.076_bb0110","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1161\/01.CIR.0000017502.58595.ED","article-title":"Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies","volume":"105","author":"Doehner","year":"2002","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ijcard.2021.11.076_bb0115","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/jcsm.12017","article-title":"Febuxostat improves outcome in a rat model of cancer cachexia","volume":"6","author":"Konishi","year":"2015","journal-title":"J. Cachexia. Sarcopenia Muscle"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527321019677?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527321019677?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T20:56:01Z","timestamp":1759092961000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527321019677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":23,"alternative-id":["S0167527321019677"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2021.11.076","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of febuxostat on clinical outcomes in patients with hyperuricemia and cardiovascular disease","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2021.11.076","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}